Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD). Consis...

Full description

Bibliographic Details
Main Authors: Olivier Devuyst, Arlene B. Chapman, Susan E. Shoaf, Frank S. Czerwiec, Jaime D. Blais
Format: Article
Language:English
Published: Elsevier 2017-11-01
Series:Kidney International Reports
Subjects:
aquaretic adverse events
autosomal dominant polycystic kidney disease
discontinuation
drug safety
tolerability
tolvaptan
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024917303054

Internet

http://www.sciencedirect.com/science/article/pii/S2468024917303054

Similar Items